Bristol Myers Squibb to Participate in Upcoming Investor Conferences

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the company will participate in two upcoming investor conferences in September 2024.

Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer, and David Elkins, Executive Vice President, Chief Financial Officer, will take part in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024. They will answer questions about the company beginning at 1:05 p.m. ET.

Adam Lenkowsky, Executive Vice President, Chief Commercialization Officer, will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on September 6, 2024. He will answer questions about the company beginning at 9:30 a.m. ET.

Investors and the general public are invited to listen to both sessions at their respective times by visiting http://investor.bms.com. An archived edition of each session will be available following its conclusion.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X (formerly Twitter), YouTube, Facebook, and Instagram.

corporatefinancial-news

View source version on businesswire.com: https://www.businesswire.com/news/home/20240827567364/en/

Media:
[email protected]

Investors:
[email protected]

Source: Bristol Myers Squibb

You May Also Be Interested In

• Socure and Aeropay Reduce Onboarding Friction to Only a Phone Number and Two Clicks
• BUUU Group Limited Signs Definitive Agreement to Acquire Majority Stake in Brightray Science Inc. and Over US$60 Million of Private Placements, Making Industrialized AI Data Center Delivery Its Core G
• Plural Brings More Than $1 Billion in Energy and Compute Infrastructure to Market in 12 Months